Lumos Diagnostics Secures $3 Million BARDA Funding for US Diagnostic Test Study; Shares Climb 11%

MT Newswires Live10-03

Lumos Diagnostics (ASX:LDX) secured nearly $3 million in funding from the Biomedical Advanced Research and Development Authority (BARDA) in the US for a study on its FebriDx diagnostic test in the country, according to a Thursday filing with the Australian bourse.

FebriDx is a point-of-care diagnostic test that can identify if a certain respiratory infection is caused by a bacteria or a virus to ensure proper treatment.

BARDA, part of the US Department of Health and Human Services' Administration for Strategic Preparedness and Response, will provide regulatory expertise and support in obtaining a Clinical Laboratory Improvement Amendments waiver from the US Food and Drug Administration for the proposed study.

The biotech company's shares climbed almost 11% in recent Thursday trade.

Price (AUD): $0.04, Change: $+0.004, Percent Change: +10.81%

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2472540046?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-03 14:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2472540046","market":"sh","top_or_hot":-1,"title":"Lumos Diagnostics Secures $3 Million BARDA Funding for US Diagnostic Test Study; Shares Climb 11%","media":"MT Newswires Live","content":"<html><body><p> Lumos Diagnostics (ASX:LDX) secured nearly $3 million in funding from the Biomedical Advanced Research and Development Authority (BARDA) in the US for a study on its FebriDx diagnostic test in the country, according to a Thursday filing with the Australian bourse.</p><p>FebriDx is a point-of-care diagnostic test that can identify if a certain respiratory infection is caused by a bacteria or a virus to ensure proper treatment.</p><p>BARDA, part of the US Department of Health and Human Services' Administration for Strategic Preparedness and Response, will provide regulatory expertise and support in obtaining a Clinical Laboratory Improvement Amendments waiver from the US Food and Drug Administration for the proposed study.</p><p>The biotech company's shares climbed almost 11% in recent Thursday trade.</p><p>Price (AUD): $0.04, Change: $+0.004, Percent Change: +10.81%</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Lumos Diagnostics Secures $3 Million BARDA Funding for US Diagnostic Test Study; Shares Climb 11%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLumos Diagnostics Secures $3 Million BARDA Funding for US Diagnostic Test Study; Shares Climb 11%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-03 14:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Lumos Diagnostics (ASX:LDX) secured nearly $3 million in funding from the Biomedical Advanced Research and Development Authority (BARDA) in the US for a study on its FebriDx diagnostic test in the ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7126","symbol_name":"医疗保健用品","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2472540046","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2472540046","pubTimestamp":1727935543,"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Lumos Diagnostics  secured nearly $3 million in funding from the Biomedical Advanced Research and Development Authority  in the US for a study on its FebriDx diagnostic test in the country, according to a Thursday filing with the Australian bourse.FebriDx is a point-of-care diagnostic test that can identify if a certain respiratory infection is caused by a bacteria or a virus to ensure proper treatment.BARDA, part of the US Department of Health and Human Services' Administration for Strategic Preparedness and Response, will provide regulatory expertise and support in obtaining a Clinical Laboratory Improvement Amendments waiver from the US Food and Drug Administration for the proposed study.The biotech company's shares climbed almost 11% in recent Thursday trade.Price : $0.04, Change: $+0.004, Percent Change: +10.81%","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7126":"医疗保健用品","LDX.AU":"LUMOS DIAGNOSTICS HOLDINGS L","BK4125":"广播","AUD":"Audacy Inc."},"translate_title":"Lumos Diagnostics获得BARDA 300万美元资金用于美国病诊断测试研究；股价上涨11%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AUD":1,"LDX.AU":0.9},"content_text":"Lumos Diagnostics (ASX:LDX) secured nearly $3 million in funding from the Biomedical Advanced Research and Development Authority (BARDA) in the US for a study on its FebriDx diagnostic test in the country, according to a Thursday filing with the Australian bourse.FebriDx is a point-of-care diagnostic test that can identify if a certain respiratory infection is caused by a bacteria or a virus to ensure proper treatment.BARDA, part of the US Department of Health and Human Services' Administration for Strategic Preparedness and Response, will provide regulatory expertise and support in obtaining a Clinical Laboratory Improvement Amendments waiver from the US Food and Drug Administration for the proposed study.The biotech company's shares climbed almost 11% in recent Thursday trade.Price (AUD): $0.04, Change: $+0.004, Percent Change: +10.81%","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2472540046"}